Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 LAR in inoperable or recurrent thymoma
NCT02021942Phase 2Completed
- Start
- Mar 2012
- Primary completion
- Oct 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pasireotide LAR in thymoma. Primary endpoint: Percent Change in Tumor Volume at 6 months. Started Mar 2012; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
thymoma
Beyond the preview
Go deeper on NCT02021942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021942.